HCC78 Cells

HCC78 is a cell line derived from a primary tumor of a lung adenocarcinoma, specifically a subtype known as mucinous bronchioloalveolar carcinoma. This cell line was established from a male adult patient. HCC78 cells are particularly noted for harboring a unique chromosomal rearrangement involving the ROS1 and SLC34A2 genes, which results in the SLC34A2-ROS1 fusion protein. This fusion protein has been implicated in oncogenic signaling pathways, making HCC78 a valuable model for studying the molecular mechanisms of ROS1 fusion-positive lung cancers and for testing targeted therapies against ROS1.

In research contexts, HCC78 has been utilized extensively to explore the efficacy and mechanism of action of ROS1 inhibitors. These studies have demonstrated the cell line’s utility in preclinical assessments of drug sensitivity, resistance mechanisms, and the cellular pathways affected by ROS1 activity. The cell line grows adherently and exhibits epithelial-like morphology, which is characteristic of bronchioloalveolar tumors. The genetic and phenotypic features of HCC78 make it an essential tool for lung cancer research, especially for investigations focused on targeted therapies and personalized medicine in the treatment of ROS1-positive cancers.